Suppr超能文献

脑膜瘤立体定向放射外科治疗后水肿的危险因素。

Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomas.

机构信息

Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA.

出版信息

Neurosurgery. 2012 Mar;70(3):639-45. doi: 10.1227/NEU.0b013e3182351ae7.

Abstract

BACKGROUND

Peritumoral edema is a recognized complication following stereotactic radiosurgery (SRS).

OBJECTIVE

To evaluate the risk of posttreatment peritumoral edema following SRS for intracranial meningiomas and determine predictive factors.

METHODS

Between 2002 and 2008, 173 evaluable patients underwent CyberKnife or Gamma Knife SRS for meningiomas. Eighty-four patients (49%) had prior surgical resections, 13 patients had World Health Organization grade II (atypical) meningiomas, and 117 patients had a neurological deficit before SRS. Sixty-two tumors were in parasagittal, parafalcine, and convexity locations. The median tumor volume was 4.7 mL (range, 0.1-231.8 mL). The median prescribed dose and median prescribed biologically equivalent dose were 15 Gy (range, 9-40 Gy) and 67 Gy (range, 14-116 Gy), respectively. Ninety-seven patients were treated with single-fraction SRS, 74 received 2 to 5 fractions, and 2 received >5 fractions.

RESULTS

The median follow-up was 21.0 months. Thirteen patients (8%) developed symptomatic peritumoral edema, with a median onset time of 4.5 months (range, 0.2-9.5 months). The 3-, 6-, 12-, and 24-month actuarial symptomatic edema rates were 2.9%, 4.9%, 7.7%, and 8.5%, respectively. The crude tumor control rate was 94%. On univariate analysis, large tumor volume (P = .01) and single-fraction SRS (P = .04) were predictive for development of posttreatment edema.

CONCLUSION

SRS meningioma treatment demonstrated a low incidence of toxicity; however, large tumor volumes and single-fraction SRS treatment had an increased risk for posttreatment edema. Risk factors for edema should be considered in meningiomas treatment.

摘要

背景

瘤周水肿是立体定向放射外科(SRS)后公认的并发症。

目的

评估颅内脑膜瘤 SRS 后治疗后瘤周水肿的风险,并确定预测因素。

方法

2002 年至 2008 年间,173 例可评估患者接受 CyberKnife 或伽玛刀 SRS 治疗脑膜瘤。84 例患者(49%)有既往手术切除史,13 例患者有世界卫生组织 2 级(非典型)脑膜瘤,117 例患者在 SRS 前有神经功能缺损。62 个肿瘤位于矢状旁、镰旁和凸面。肿瘤体积中位数为 4.7 mL(范围,0.1-231.8 mL)。中位处方剂量和中位生物等效剂量分别为 15 Gy(范围,9-40 Gy)和 67 Gy(范围,14-116 Gy)。97 例患者接受单次分割 SRS 治疗,74 例接受 2-5 次分割,2 例接受>5 次分割。

结果

中位随访时间为 21.0 个月。13 例(8%)患者出现症状性瘤周水肿,中位发病时间为 4.5 个月(范围,0.2-9.5 个月)。3、6、12 和 24 个月的累积症状性水肿发生率分别为 2.9%、4.9%、7.7%和 8.5%。肿瘤粗控制率为 94%。单因素分析显示,肿瘤体积大(P =.01)和单次分割 SRS(P =.04)是治疗后水肿发生的预测因素。

结论

SRS 脑膜瘤治疗的毒性发生率较低;然而,大肿瘤体积和单次分割 SRS 治疗增加了治疗后水肿的风险。在脑膜瘤治疗中应考虑水肿的危险因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验